Summary
Global Markets Direct’s, ‘Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H2 2016’, provides an overview of the Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Reflux Esophagitis (Gastroesophageal Reflux Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Reflux Esophagitis (Gastroesophageal Reflux Disease)
- The report reviews pipeline therapeutics for Reflux Esophagitis (Gastroesophageal Reflux Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Reflux Esophagitis (Gastroesophageal Reflux Disease) therapeutics and enlists all their major and minor projects
- The report assesses Reflux Esophagitis (Gastroesophageal Reflux Disease) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Reflux Esophagitis (Gastroesophageal Reflux Disease)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Reflux Esophagitis (Gastroesophageal Reflux Disease)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Ahn-Gook Pharmaceutical Co., Ltd.
Alveonix AG
Cempra, Inc.
Daewoong Pharmaceutical Co., Ltd.
Eisai Co., Ltd.
Ironwood Pharmaceuticals, Inc.
Jeil Pharmaceutical Co., Ltd.
Johnson & Johnson
RaQualia Pharma Inc.
Vecta Ltd.
Wockhardt Limited
Yuyu Pharma, Inc
'
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Reflux Esophagitis (Gastroesophageal Reflux Disease) Overview 9
Therapeutics Development 10
Pipeline Products for Reflux Esophagitis (Gastroesophageal Reflux Disease) - Overview 10
Pipeline Products for Reflux Esophagitis (Gastroesophageal Reflux Disease) - Comparative Analysis 11
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Therapeutics under Development by Companies 12
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Therapeutics under Investigation by Universities/Institutes 13
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Products under Development by Companies 17
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Products under Investigation by Universities/Institutes 19
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Companies Involved in Therapeutics Development 20
Ahn-Gook Pharmaceutical Co., Ltd. 20
Alveonix AG 21
Cempra, Inc. 22
Daewoong Pharmaceutical Co., Ltd. 23
Eisai Co., Ltd. 24
Ironwood Pharmaceuticals, Inc. 25
Jeil Pharmaceutical Co., Ltd. 26
Johnson & Johnson 27
RaQualia Pharma Inc. 28
Vecta Ltd. 29
Wockhardt Limited 30
Yuyu Pharma, Inc. 31
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Combination Products 33
Assessment by Target 34
Assessment by Mechanism of Action 36
Assessment by Route of Administration 38
Assessment by Molecule Type 40
Drug Profiles 42
(lansoprazole + omeprazole) - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Ax-8 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
CEM-031 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
DWJ-1367 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
DWJ-206 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
E-3710 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
esomeprazole magnesium - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
G-17DT - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
IW-3718 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
JNJ-26070109 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
JP-1366 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
netazepide - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
omeprazole - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
pantoprazole - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
RQ-00000774 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
Small Molecule to Inhibit Potassium Transporting ATPase Alpha Chain 1 Inhibitor for Peptic Ulcers and Reflux Esophagitis - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
Small Molecules to Block Proton Pump for Gastrointestinal Disorders - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
Small Molecules to Inhibit Tubulin for Barrett's Esophageal Adenocarcinoma - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
tegoprazan - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
tenatoprazole - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
TR-2A - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
YY-DXR - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects 70
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products 73
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Product Development Milestones 76
Featured News & Press Releases 76
Mar 23, 2016: Ironwood Pharmaceuticals Initiates Phase IIb Clinical Trial of IW-3718 in Refractory Gastroesophageal Reflux Disease 76
Feb 18, 2016: RaQualia Receives a Patent Allowance for Acid Pump Antagonist in Korea 76
Oct 19, 2015: Ironwood Highlights Refractory GERD Research at the American College of Gastroenterology 2015 Annual Scientific Meeting 77
Feb 04, 2015: Ironwood Reports Positive Top-Line Data from Exploratory Phase IIa Trial Of IW-3718 in Refractory Gastroesophageal Reflux Disease 77
Mar 18, 2014: Ironwood Pharmaceuticals Initiates Phase II Clinical Study of IW-3718 in Refractory Gastroesophageal Reflux Disease 78
Sep 04, 2012: Santarus Announces Appellate Court Reversal In Part Of Zegerid Invalidity Decision 79
Mar 29, 2011: RaQualia Pharma Announces Successful Results From Phase I Study Of Acid Pump Antagonist 79
Apr 01, 2010: Santarus Announces Launch of ZEGERID OTC by Schering-Plough Consumer HealthCare 80
Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck 81
Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations 81
Dec 22, 2009: Santarus Receives Previously Announced $20 Million Milestone for FDA Approval of ZEGERID OTC 82
Dec 05, 2009: Santarus Receives FDA Approval for Immediate-Release Omeprazole 82
Dec 01, 2009: Santarus Announces FDA Approval of Schering-Plough HealthCare Products' ZEGERID OTC 82
Oct 26, 2009: Santarus To Present Positive Data From Two Investigator-Initiated Studies With ZEGERID At ACG 2009 Meeting 83
Oct 12, 2009: Santarus and Norgine Enter License for ZEGERID Immediate-Release Omeprazole Products in Europe 84
Appendix 85
Methodology 85
Coverage 85
Secondary Research 85
Primary Research 85
Expert Panel Validation 85
Contact Us 85
Disclaimer 86
List of Tables
Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease), H2 2016 10
Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease) - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Number of Products under Investigation by Universities/Institutes, H2 2016 13
Comparative Analysis by Late Stage Development, H2 2016 14
Comparative Analysis by Clinical Stage Development, H2 2016 15
Comparative Analysis by Early Stage Development, H2 2016 16
Products under Development by Companies, H2 2016 17
Products under Development by Companies, H2 2016 (Contd..1) 18
Products under Investigation by Universities/Institutes, H2 2016 19
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Ahn-Gook Pharmaceutical Co., Ltd., H2 2016 20
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Alveonix AG, H2 2016 21
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Cempra, Inc., H2 2016 22
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016 23
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Eisai Co., Ltd., H2 2016 24
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Ironwood Pharmaceuticals, Inc., H2 2016 25
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2016 26
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Johnson & Johnson, H2 2016 27
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by RaQualia Pharma Inc., H2 2016 28
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Vecta Ltd., H2 2016 29
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Wockhardt Limited, H2 2016 30
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Yuyu Pharma, Inc., H2 2016 31
Assessment by Monotherapy Products, H2 2016 32
Assessment by Combination Products, H2 2016 33
Number of Products by Stage and Target, H2 2016 35
Number of Products by Stage and Mechanism of Action, H2 2016 37
Number of Products by Stage and Route of Administration, H2 2016 39
Number of Products by Stage and Molecule Type, H2 2016 41
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects, H2 2016 70
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects (Contd..1), H2 2016 71
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects (Contd..2), H2 2016 72
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products, H2 2016 73
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products (Contd..1), H2 2016 74
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products (Contd..2), H2 2016 75
List of Figures
Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease), H2 2016 10
Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease) - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Number of Products under Investigation by Universities/Institutes, H2 2016 13
Comparative Analysis by Clinical Stage Development, H2 2016 15
Comparative Analysis by Early Stage Products, H2 2016 16
Assessment by Monotherapy Products, H2 2016 32
Number of Products by Targets, H2 2016 34
Number of Products by Stage and Targets, H2 2016 34
Number of Products by Mechanism of Actions, H2 2016 36
Number of Products by Stage and Mechanism of Actions, H2 2016 36
Number of Products by Routes of Administration, H2 2016 38
Number of Products by Stage and Routes of Administration, H2 2016 38
Number of Products by Molecule Types, H2 2016 40
Number of Products by Stage and Molecule Types, H2 2016 40
